Clinical management of BRCA1 and BRCA2 mutation carriers

被引：48

作者：

Domchek, S. M.

Weber, B. L.

机构：

[1] Univ Penn, Abramson Canc Ctr, Canc Risk Evaluat Program, Philadelphia, PA 19104 USA

[2] GlaxoSmithKline Inc, Philadelphia, PA USA

来源：

ONCOGENE | 2006年 / 25卷 / 43期

关键词：

BRCA1; BRCA2; oophorectomy; breast cancer; ovarian cancer; management;

D O I：

10.1038/sj.onc.1209881

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.

引用

页码：5825 / 5831

页数：7

共 67 条

[11] Improved survival in women with BRCA-associated ovarian carcinoma [J].

Cass, I ;

Baldwin, RL ;

Varkey, T ;

Moslehi, R ;

Narod, SA ;

Karlan, BY .

CANCER, 2003, 97 (09) :2187-2195

[12] Peritoneal lavage cytology: An assessment of its value during prophylactic oophorectomy [J].

Colgan, TJ ;

Boerner, SL ;

Murphy, J ;

Cole, DEC ;

Narod, S ;

Rosen, B .

GYNECOLOGIC ONCOLOGY, 2002, 85 (03) :397-403

[13] Occult carcinoma in prophylactic oophorectomy specimens - Prevalence and association with BRCA germline mutation status [J].

Colgan, TJ ;

Murphy, J ;

Cole, DEC ;

Narod, S ;

Rosen, B .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (10) :1283-1289

[14]

COMCHEK SM, 2006, LANCET ONCOL, V7, P223

[15] The Fanconi anaemia BRCA pathway [J].

D'Andrea, AD ;

Grompe, M .

NATURE REVIEWS CANCER, 2003, 3 (01) :23-34

[16] Breast cancer risk following bilateral oophorectorny in BRCA1 and BRCA2 mutation carriers:: An international case-control study [J].

Eisen, A ;

Lubinski, J ;

Klijn, J ;

Moller, P ;

Lynch, HT ;

Offit, K ;

Weber, B ;

Rebbeck, T ;

Neuhausen, SL ;

Ghadirian, P ;

Foulkes, WD ;

Gershoni-Baruch, R ;

Friedman, E ;

Rennert, G ;

Wagner, T ;

Isaacs, C ;

Kim-Sing, C ;

Ainsworth, P ;

Sun, P ;

Narod, SA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) :7491-7496

[17] The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy [J].

Eitan, Ram ;

Soslow, Robert ;

Lin, Oscar ;

Kauff, Noah D. ;

Liu, Lisa ;

Barakat, Richard R. ;

Chi, Dennis S. .

GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :315-318

[18] Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy [J].

Farmer, H ;

McCabe, N ;

Lord, CJ ;

Tutt, ANJ ;

Johnson, DA ;

Richardson, TB ;

Santarosa, M ;

Dillon, KJ ;

Hickson, I ;

Knights, C ;

Martin, NMB ;

Jackson, SP ;

Smith, GCM ;

Ashworth, A .

NATURE, 2005, 434 (7035) :917-921

[19] Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].

Fisher, B ;

Costantino, JP ;

Wickerham, DL ;

Cecchini, RS ;

Cronin, WM ;

Robidoux, A ;

Bevers, TB ;

Kavanah, MT ;

Atkins, JN ;

Margolese, RG ;

Runowicz, CD ;

James, JM ;

Ford, LG ;

Wolmark, N .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (22) :1652-1662

[20] Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J].

Fisher, B ;

Costantino, JP ;

Wickerham, DL ;

Redmond, CK ;

Kavanah, M ;

Cronin, WM ;

Vogel, V ;

Robidoux, A ;

Dimitrov, N ;

Atkins, J ;

Daly, M ;

Wieand, S ;

Tan-Chiu, E ;

Ford, L ;

Wolmark, N .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (18) :1371-1388

← 1 2 3 4 5 6 7 →